JP2024527424A - コロナウイルス関連疾患の治療のための化合物及び組成物 - Google Patents
コロナウイルス関連疾患の治療のための化合物及び組成物 Download PDFInfo
- Publication number
- JP2024527424A JP2024527424A JP2024503613A JP2024503613A JP2024527424A JP 2024527424 A JP2024527424 A JP 2024527424A JP 2024503613 A JP2024503613 A JP 2024503613A JP 2024503613 A JP2024503613 A JP 2024503613A JP 2024527424 A JP2024527424 A JP 2024527424A
- Authority
- JP
- Japan
- Prior art keywords
- isoquinolin
- carbonitrile
- oxoimidazolidine
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224793P | 2021-07-22 | 2021-07-22 | |
| US63/224,793 | 2021-07-22 | ||
| US202163289009P | 2021-12-13 | 2021-12-13 | |
| US63/289,009 | 2021-12-13 | ||
| PCT/IB2022/056712 WO2023002409A1 (en) | 2021-07-22 | 2022-07-20 | Compounds and compositions for the treatment of coronaviral related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527424A true JP2024527424A (ja) | 2024-07-24 |
| JP2024527424A5 JP2024527424A5 (https=) | 2025-07-17 |
Family
ID=82742919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503613A Pending JP2024527424A (ja) | 2021-07-22 | 2022-07-20 | コロナウイルス関連疾患の治療のための化合物及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250092016A1 (https=) |
| EP (1) | EP4373814A1 (https=) |
| JP (1) | JP2024527424A (https=) |
| KR (1) | KR20240038996A (https=) |
| AU (1) | AU2022315058A1 (https=) |
| CA (1) | CA3226758A1 (https=) |
| MX (1) | MX2024000986A (https=) |
| PY (1) | PY2261702A (https=) |
| TW (1) | TW202321210A (https=) |
| UY (1) | UY39863A (https=) |
| WO (1) | WO2023002409A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| JP7624093B2 (ja) | 2022-04-08 | 2025-01-29 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物 |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
| WO2025125695A2 (en) * | 2024-12-17 | 2025-06-19 | Medchemica Consultancy Ltd | Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1200825B (de) * | 1962-01-13 | 1965-09-16 | Hoechst Ag | Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen |
| JP2012530763A (ja) * | 2009-06-26 | 2012-12-06 | ノバルティス アーゲー | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 |
-
2022
- 2022-07-19 UY UY0001039863A patent/UY39863A/es unknown
- 2022-07-19 TW TW111127023A patent/TW202321210A/zh unknown
- 2022-07-19 PY PY202202261702A patent/PY2261702A/es unknown
- 2022-07-20 CA CA3226758A patent/CA3226758A1/en active Pending
- 2022-07-20 EP EP22748094.4A patent/EP4373814A1/en active Pending
- 2022-07-20 MX MX2024000986A patent/MX2024000986A/es unknown
- 2022-07-20 WO PCT/IB2022/056712 patent/WO2023002409A1/en not_active Ceased
- 2022-07-20 KR KR1020247005669A patent/KR20240038996A/ko active Pending
- 2022-07-20 JP JP2024503613A patent/JP2024527424A/ja active Pending
- 2022-07-20 AU AU2022315058A patent/AU2022315058A1/en active Pending
- 2022-07-20 US US18/580,986 patent/US20250092016A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1200825B (de) * | 1962-01-13 | 1965-09-16 | Hoechst Ag | Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen |
| JP2012530763A (ja) * | 2009-06-26 | 2012-12-06 | ノバルティス アーゲー | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 |
Non-Patent Citations (2)
| Title |
|---|
| CHANDE, MADHUKAR S. ET AL.: "Synthesis of new 1-[benzothiazol-2-yl]triazole derivatives as potential anti-cancer agents", INDIAN JOURNAL OF CHEMISTRY. SECTION B: ORGANIC CHEMISTRY. INCLUDING MEDICINAL CHEMISTRY, vol. 34, JPN6026012317, 1995, pages 654 - 657, ISSN: 0005829436 * |
| EL-ANSARY, S. L. ET AL.: "Synthesis of trioxo-perhydro-imidazolyl-benzopyrones with hypnotic activity", EGYPTIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. Vol.36, No.1-6, JPN6026012316, 1995, pages 219 - 233, ISSN: 0005829435 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024000986A (es) | 2024-02-12 |
| PY2261702A (es) | 2023-06-14 |
| TW202321210A (zh) | 2023-06-01 |
| KR20240038996A (ko) | 2024-03-26 |
| US20250092016A1 (en) | 2025-03-20 |
| UY39863A (es) | 2023-02-28 |
| EP4373814A1 (en) | 2024-05-29 |
| AU2022315058A1 (en) | 2024-02-08 |
| CA3226758A1 (en) | 2023-01-26 |
| WO2023002409A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024527424A (ja) | コロナウイルス関連疾患の治療のための化合物及び組成物 | |
| JP7097373B2 (ja) | キナーゼ阻害剤としてのアミノトリアゾロピリジン | |
| CN104922128B (zh) | 流感病毒复制抑制剂 | |
| JP5959541B2 (ja) | Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン | |
| JP7471348B2 (ja) | ブルトン型チロシンキナーゼの阻害剤及びその使用方法 | |
| TWI594997B (zh) | 流感病毒複製之抑制劑 | |
| CN107108566B (zh) | 取代的2-氮杂双环化合物以及它们作为食欲素受体调节剂的用途 | |
| CN104619702B (zh) | Ccr2的稠合环戊基拮抗剂 | |
| CA2917193A1 (en) | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators | |
| WO2022224223A1 (en) | Compounds and compositions for the treatment of coronaviral related diseases | |
| TWI712598B (zh) | 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途 | |
| AU2022255486A1 (en) | Nek7 inhibitors | |
| HK1210159A1 (en) | Mk2 inhibitors | |
| TW202233614A (zh) | 作為激酶抑制劑之三唑并吡啶化合物 | |
| EA050666B1 (ru) | Соединения и композиции для лечения заболеваний, связанных с коронавирусной инфекцией | |
| CN117651699A (zh) | 用于治疗冠状病毒相关疾病的化合物和组合物 | |
| US20250026763A1 (en) | Egfr inhibitors and methods of use thereof | |
| WO2025146502A1 (en) | Coronavirus inhibiting compounds | |
| TW202542138A (zh) | 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途 | |
| JP2026506656A (ja) | Ｓｇｋ１阻害剤としてのアミノ置換ピロロトリアジン誘導体 | |
| TW202334135A (zh) | 化合物、組合物及方法 | |
| CN113015736A (zh) | 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物 | |
| HK40012938B (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
| HK40012561B (en) | Heteroaryl compounds and their use as mer inhibitors | |
| HK1204322B (en) | Inhibitors of influenza viruses replication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250709 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250709 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260331 |